Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Longboard Pharmaceuticals logo — We Are Committed To Transforming the Lives of Patients With...

Longboard Pharmaceuticals

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.

Founded 2020 United States La Jolla, United States 81 employees Post Ipo Equity Total: $79.00M Biotechnology, Health Care +1

General Information

Company Name Longboard Pharmaceuticals
Founded Year 2020
Location United States La Jolla, United States +1
Founders / Decision Makers
Team member Team member Team member
Employees 81
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Longboard Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a mission to revolutionize the lives of patients affected by neurological and rare diseases. The company is dedicated to developing groundbreaking medications for neurological conditions by focusing on a portfolio of centrally acting product candidates. Longboard's small molecule product candidates are the result of over 20 years of GPCR research, emphasizing its commitment to innovation and scientific advancement. One of the key product candidates, LP352, is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist. Longboard is pursuing its development for the potential treatment of seizures associated with a diverse range of developmental and epileptic encephalopathies, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes. Additionally, the company is evaluating LP659, a centrally acting modulator for sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5, for the potential treatment of multiple neurological diseases. Furthermore, LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, is being developed for the potential treatment of central nervous system (CNS) diseases and disorders. Founded in 2020 and headquartered in the United States, Longboard Pharmaceuticals has recently attracted Post-IPO Equity investment at 02 January 2024, marking a significant milestone in its growth. This investment speaks to the company's potential and the confidence of its investors in the impact it can make in the biotechnology, healthcare, and pharmaceutical sectors.

Taxonomy: biopharmaceutical company, clinical-stage, neurological diseases, G protein-coupled receptors, small molecule product candidates, 5-hydroxytryptamine 2C (5-HT2C) receptor, epileptic encephalopathies, sphingosine-1-phosphate (S1P) receptor, multiple neurological diseases, cannabinoid type 2 receptor (CB2), central nervous system (CNS), drug development, clinical trials, neurological research, translational medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 02 Jan 2024
Post-IPO Equity •••••• - 07 Feb 2023
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		28 Oct 2020

Longboard Pharmaceuticals Alternatives & Competitors

Longboard Pharmaceuticals vs
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. United States

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development o...

Post Ipo Equity
59 employees
Health Care, Health and Wellness
Compare Longboard Pharmaceuticals vs Viking Therapeutics, Inc.
Longboard Pharmaceuticals vs
AELIS FARMA
AELIS FARMA France

A clinical stage biotech company opening a new frontier in pharmacology

IPO
33 employees
Compare Longboard Pharmaceuticals vs AELIS FARMA
Longboard Pharmaceuticals vs
Connect Biopharma
Connect Biopharma United States

Global Clinical Stage Company Connecting Patients with Innovation for Life

Series C
30 employees
Biotechnology, Health Care
Compare Longboard Pharmaceuticals vs Connect Biopharma

FAQ About Longboard Pharmaceuticals

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.
Longboard Pharmaceuticals was founded in 2020.
Longboard Pharmaceuticals is headquartered in La Jolla, United States.
Longboard Pharmaceuticals operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Longboard Pharmaceuticals has approximately 81 employees.
Longboard Pharmaceuticals has completed 3 funding rounds, raising a total of $79.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Longboard Pharmaceuticals include Viking Therapeutics, Inc., AELIS FARMA, Connect Biopharma, Relmada Therapeutics, Inc, Vistagen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Longboard Pharmaceuticals and Viking Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Longboard Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes